Inhibikase Stock Trading Lower After Public Offering News

This post was originally published on this site
By Stephen Nakrosis

Shares of pharmaceutical company Inhibikase Therapeutics Inc. are trading lower in Friday’s after-hours market, after the company filed with the U.S. Securities and Exchange Commission for a firm commitment public offering of 8 million shares of common stock, which the company said was “based on an assumed public offering price of $5.65 per share,” the last reported sales price of its common stock on June 7.

At 5:13 p.m. ET, the company’s shares were trading 13.53% lower, at $5.15 a share. Volume at the time topped 2,500 shares.

The company’s stock finished the day’s regular session with a 3.31% loss, closing at $5.95.

Inhibikase said it is developing therapeutics to “modify the course of Parkinson’s disease and related disorders inside and outside of the brain.”

The company has a market cap of $61.97 million, 10.06 million shares outstanding and a public float of 3.3 million shares.

–Write to Stephen Nakrosis at stephen.nakrosis@wsj.com